The oncology market includes a large number of heterogeneous indications demonstrating a wide range of unmet medical needs and incidence rates. Standard treatments for the various forms of cancer include surgery, chemotherapy, radiation therapy and hormone treatment. However, new biological products hold the most promise for changing treatment paradigms. Drugs such as therapeutic antibodies may allow for highly specific targeting of cancer cells or signaling molecules in order to potentially offer a different safety profile.
MorphoSys is currently developing proprietary cancer compounds in clinical trials.